Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
What are the benefits of becoming a remote worker? Let’s explore together.
The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.
If you’re considering preparing for your next interview, know that you need to learn the art of drafting a perfect cover letter to show that you’re a great match for the position.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
John Edwards, newly-appointed CEO of Verseau Therapeutics, is continually searching for something special.
In a conference call on Wednesday, Biogen CEO Michel Vounatsos outlined the company’s plans for commercial distribution of Aduhelm.
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.